1Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the framingham population, sixteen year follow-up study [J]. Diabetes, 1974 ,23 (2) : 105-111.
2Low H, Hoang A, Forbes J, et al. Advanced g1ycation end-products (AGEs) and functiona-lity of reverse cholesterol transport in patients with type 2 diabetes and in mouse models [J]. Diabetologia, 2012,55 (9) :2513-2521.
4Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease [J]. Brain Res, 2001 ,888 (2) :256-262.
5Hein G, Weiss C ,Lehmann G,et al. Advanced g1ycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings [J]. Ann Rheum Dis ,2006 ,65 (1) : 101-104.
6Assimakopoulos D, Danielides V, Kontogianis N, et al. Sudden hearing loss as the presenting symptom of diabetes mellitus [J]. Diabetes Res Clin Pract,2001 ,53(3) :201-203.
7Howes KA, Liu Y, Dunaief JL, et al. Receptor for advanced glycation end products and age-related macular degeneration [J]. Invest Ophthalmol Vis Sci,2004,45(i0) :3713-3720.
8Gebhardt C, Riehl A j Durchdewald M, et al. RAGE signaling sustains inflammation and promotes tumor development [J]. J Exp Med,2008,205(2) :275-285.
9Allmen EU, Koch M, Fritz G, et al. V domain of RAGE interacts with AGEs on prostate carcinoma cells [J]. Prostate, 2008 , 68 (7) :748-758.
10Brown BE, Mahroof FM ,Cook NL, et al. Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified lowdensity lipoproteins [J]. Diabetologia,2006 ,49 (4) : 775-783.
4Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：345
5Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量：117
8Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glyeation end preduets (sRAGE) in diabetes [J]. Curt Drug Targets, 2007, 8 (10) : 1 138-143.
9Liang L, Major T, Bocan T. Characterization of the promoter of human extraeenular matrix metalloproteinase inducer ( EMMPRIN ) [ J ]. Gene, 2002, 282 (1-2): 75-86.
10Yoon YW, Kwon HM, Hwang KC, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN: matrix metaLloproteinase inducer in advanced at herosclerotic plaque [ J ]. Atherosclerosis, 2005, 180 ( 1 ) : 37- 44.
